Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Pharming Group ( (PHAR) ) has issued an announcement.
On January 8, 2026, Pharming Group reported preliminary, unaudited 2025 revenues of about US$376 million, surpassing its upgraded guidance range of US$365–375 million and marking roughly 27% year‑on‑year growth, driven by continued expansion of hereditary angioedema drug RUCONEST® and strong U.S.-led uptake and geographic rollout of Joenja®. Operating expenses for 2025 are expected to land within the previously guided US$304–308 million range, highlighting tighter cost control, while the company prepares to publish full fourth-quarter and full‑year results on March 12, 2026 and to host a virtual Investor Day on February 3, 2026, where management and external clinical experts will update investors on Pharming’s advancing pipeline in primary immunodeficiencies and mitochondrial disease and outline 2026 financial guidance, underlining the group’s ambition to sustain growth and strengthen its rare‑disease positioning.
The most recent analyst rating on (PHAR) stock is a Hold with a $17.50 price target. To see the full list of analyst forecasts on Pharming Group stock, see the PHAR Stock Forecast page.
Spark’s Take on PHAR Stock
According to Spark, TipRanks’ AI Analyst, PHAR is a Neutral.
Pharming Group’s overall score is driven by strong technical indicators and a positive earnings call, which highlight growth and operational improvements. However, the high P/E ratio and low profitability metrics weigh down the score, indicating valuation concerns and profitability challenges.
To see Spark’s full report on PHAR stock, click here.
More about Pharming Group
Pharming Group N.V. is a global biopharmaceutical company focused on rare, debilitating and life‑threatening diseases, developing and commercializing a portfolio of innovative medicines, including small molecules and biologics. Headquartered in Leiden, the Netherlands, the company has a significant U.S. presence and markets products such as RUCONEST® and Joenja® for patients with high unmet medical needs.
Average Trading Volume: 20,796
Technical Sentiment Signal: Buy
Current Market Cap: $1.14B
For an in-depth examination of PHAR stock, go to TipRanks’ Overview page.